Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
455.48
-1.88 (-0.41%)
At close: Dec 5, 2025, 4:00 PM EST
455.97
+0.49 (0.11%)
After-hours: Dec 5, 2025, 7:46 PM EST
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $3.08B in the quarter ending September 30, 2025, with 10.99% growth. This brings the company's revenue in the last twelve months to $11.69B, up 10.04% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.69B
Revenue Growth
+10.04%
P/S Ratio
9.97
Revenue / Employee
$1,921,852
Employees
6,100
Market Cap
115.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
| Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
| Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
| Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
| Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
| Dec 31, 2019 | 4.16B | 1.12B | 36.59% |
| Dec 31, 2018 | 3.05B | 558.95M | 22.46% |
| Dec 31, 2017 | 2.49B | 786.48M | 46.20% |
| Dec 31, 2016 | 1.70B | 669.84M | 64.89% |
| Dec 31, 2015 | 1.03B | 451.92M | 77.86% |
| Dec 31, 2014 | 580.42M | -631.56M | -52.11% |
| Dec 31, 2013 | 1.21B | -315.07M | -20.63% |
| Dec 31, 2012 | 1.53B | 116.42M | 8.25% |
| Dec 31, 2011 | 1.41B | 1.27B | 883.91% |
| Dec 31, 2010 | 143.37M | 41.48M | 40.71% |
| Dec 31, 2009 | 101.89M | -73.62M | -41.94% |
| Dec 31, 2008 | 175.50M | -23.51M | -11.81% |
| Dec 31, 2007 | 199.01M | -17.34M | -8.02% |
| Dec 31, 2006 | 216.36M | 55.47M | 34.47% |
| Dec 31, 2005 | 160.89M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VRTX News
- 3 hours ago - Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals? - The Motley Fool
- 15 hours ago - Vertex's gene therapy shows promise in younger children with blood disorders - Reuters
- 15 hours ago - Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions - Business Wire
- 2 days ago - 1 Reason I'll Never Sell Vertex Pharmaceuticals Stock - The Motley Fool
- 3 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 3 days ago - 2 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - The Motley Fool
- 5 days ago - 3 Top Stocks to Buy in December - The Motley Fool
- 9 days ago - Where Will Vertex Pharmaceuticals Be in 5 Years - The Motley Fool